INOVIO PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INOVIO PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $8.79M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $2.64M | Mar 14, 2018 |
| FY2017 | Jun 30, 2017 | $20.41M | Mar 14, 2018 |
| FY2017 | Mar 31, 2017 | $10.38M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $8.51M | Mar 14, 2018 |
| FY2017 | Sep 30, 2016 | $12.54M | Mar 14, 2018 |
| FY2017 | Jun 30, 2016 | $6.20M | Mar 14, 2018 |
| FY2017 | Mar 31, 2016 | $8.11M | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $5.94M | Mar 15, 2017 |
| FY2016 | Sep 30, 2015 | $24.18M | Mar 15, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.3K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $217.8K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $832.0K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $10.26M | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | $1.77M | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | $5.58M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $236.2K | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $267.2K | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $1.33M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $279.5K | Mar 1, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $42.22M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $35.37M | Mar 14, 2018 |
| FY2017 | Dec 31, 2015 | $40.57M | Mar 14, 2018 |
| FY2016 | Dec 31, 2014 | $10.46M | Mar 15, 2017 |
| FY2015 | Dec 31, 2013 | $13.47M | Mar 14, 2016 |
| FY2014 | Dec 31, 2012 | $4.12M | Mar 16, 2015 |
| FY2013 | Dec 31, 2011 | $9.80M | Mar 17, 2014 |
| FY2012 | Dec 31, 2010 | $6.14M | Mar 18, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.95M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($107.25M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($135.12M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($279.82M) | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | ($303.66M) | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | ($24.34M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $19.17M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($128.70M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($32.54M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($37.66M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($86.82M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($112.40M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($143.94M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($267.57M) | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | ($301.22M) | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | ($29.34M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($36.33M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($33.18M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($25.23M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($30.42M) | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.21M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $75.62M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $86.68M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $187.65M | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | $249.24M | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | $26.30M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $26.46M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $22.38M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $19.11M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $22.00M | Mar 1, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($88.63M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($104.08M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($124.37M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($216.22M) | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | ($215.71M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | ($177.98M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($97.85M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($73.55M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($63.21M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($62.56M) | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.7K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $487.8K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $320.9K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $969.2K | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | $1.23M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $1.52M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $987.9K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $2.09M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $10.29M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $2.74M | Mar 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.31M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $113.20M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $170.95M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $348.53M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $495.94M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $539.77M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $143.95M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $131.11M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $187.24M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $173.71M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.21M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $44.69M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $53.60M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $126.17M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $96.27M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $78.63M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $138.55M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $44.08M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $44.75M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $50.33M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.10M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $68.50M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $117.35M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $222.36M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $399.67M | Mar 6, 2024 |
| FY2023 | Dec 31, 2020 | $461.14M | Mar 6, 2024 |
| FY2020 | Dec 31, 2019 | $3.44M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $86.94M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $142.39M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $123.28M | Mar 14, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 6, 2024 |
| FY2023 | Dec 31, 2022 | $10.51M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $10.51M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $10.51M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $10.51M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $10.51M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $10.51M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $10.51M | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $10.11M | Mar 15, 2017 |
| FY2015 | Dec 31, 2014 | $10.11M | Mar 14, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.82B) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($1.73B) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($1.62B) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($1.49B) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($1.21B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($906.20M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($739.79M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($620.43M) | Mar 12, 2020 |
| FY2018 | Jan 1, 2018 | ($523.12M) | Mar 12, 2019 |
| FY2018 | Dec 31, 2017 | ($523.36M) | Mar 12, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.27M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $65.81M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $14.31M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $46.33M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $71.14M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $250.73M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $22.20M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $23.69M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $23.79M | Mar 12, 2019 |
| FY2018 | Dec 31, 2016 | $19.14M | Mar 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (14) | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | (17) | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (14) | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | (17) | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 69.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 36.10M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 22.79M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 21.09M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 217.38M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 186.85M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 101.36M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 97.23M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 90.36M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 74.06M | Mar 14, 2018 |